Azurity Archives
News and events as they happenAzurity Pharmaceuticals Announces the FDA Approval of FerabrightTM (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the Brain
Woburn, MA — October 17, 2025 — Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ferabright™ (ferumoxytol injection), the first and only iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.1
Azurity Pharmaceuticals, Inc. Announces the Availability of BRYNOVIN™ (sitagliptin), the First and Only Oral Liquid Sitagliptin
FOR IMMEDIATE RELEASE Woburn, MA — July 31, 2025 — Azurity Pharmaceuticals, Inc. announced today the availability of BRYNOVIN™ (sitagliptin) oral solution, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. BRYNOVIN is not recommended in patients with type 1 diabetes and has not been studied in patients with a history of pancreatitis.
George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US
An innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, that can deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, as demonstrated in clinical trials, with an established safety profile
Azurity Pharmaceuticals announces the FDA Approval of XIFYRM™ (meloxicam injection) for the Management of Moderate-to-Severe Pain in Adults
FOR IMMEDIATE RELEASE Woburn, MA — June 10, 2025 — Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved XIFYRMTM (meloxicam injection) an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.
